
Proposals that would have seen spending on medicines in the UK increase by around £1 billion over the next three years have been shelved, according to the Government.
Officials launched a review of the voluntary scheme for branded medicines pricing, access and growth (Vpag) – an agreement to control the cost of sales of branded medicines to the NHS – earlier this year.